Cardiovascular Clinical Trials Industry - Regional Synopsis
North American Market Statistics
North America industry is estimated to hold largest revenue share of 34% by 2037. The region is home to several established contract research organizations (CROs) that specialize in cardiovascular clinical trials. These CROs have the expertise, infrastructure, and resources necessary to conduct highly complex cardiovascular research.
In addition, pharmaceutical companies in North America are investing heavily in research and development (R&D) to improve health care and develop new treatments. This increase in R&D expenditure drives demand for clinical trials, especially in the cardiovascular field. Moreover, the fusion of real-world data and genomic advances is increasing the demand for evaluating the value of personalized medicine. This trend is most evident in North America, where there is a strong focus on integrating real-world data with phase IV clinical trials for payer adoption and health technology research
The United States represents the largest market for clinical cardiovascular research. Cardiovascular disease (CVD) is the leading cause of death in the United States, accounting for 928,741 deaths by 2020. Due to the availability of new resources and technological changes used in clinical research, cardiovascular clinical trials are conducted in the country.
APAC Market Analysis
The Asia Pacific region will also encounter huge growth for the cardiovascular clinical trials market during the forecast period and will hold the second position. Over the past 2 decades, the number of CVD-related deaths in Asia increased from 5.6 million to 1.08 million. Approximately 39% of these CVD deaths were premature, i.e., they occurred in individuals younger than 70 years, which was significantly higher than premature CVD deaths (23%) in the US.
The expansion of independent clinics in the region is increasing the demand for cardiovascular clinical trials. Supportive regulatory developments, particularly in China and India, are making regional trials more affordable and accessible. Telemedicine and the use of wearable devices for monitoring patients undergoing clinical trials enable cost-effective and efficient management of clinical trials, thus supporting market growth. The growing elderly population of the Asia Pacific region is increasing the prevalence of cardiovascular diseases, and there is a need for clinical research.
In 2022, China accounted for 29% of global clinical trial activity, up from 17% a decade ago. Cardiovascular contributed 9% by 2022, compared with 11% over five years and 12% over 10 years.
